Literature DB >> 12842895

Sequence-specific peptide aptamers, interacting with the intracellular domain of the epidermal growth factor receptor, interfere with Stat3 activation and inhibit the growth of tumor cells.

Claudia Buerger1, Kerstin Nagel-Wolfrum, Christian Kunz, Ilka Wittig, Karin Butz, Felix Hoppe-Seyler, Bernd Groner.   

Abstract

Receptor tyrosine kinases of the epidermal growth factor (EGF) receptor family regulate essential cellular functions such as proliferation, survival, migration, and differentiation but also play central roles in the etiology and progression of tumors. We have identified short peptide sequences from a random peptide library integrated into the thioredoxin scaffold protein, which specifically bind to the intracellular domain of the EGF receptor (EGFR). These molecules have the potential to selectively inhibit specific aspects of EGF receptor signaling and might become valuable as anticancer agents. Intracellular expression of the aptamer encoding gene construct KDI1 or introduction of bacterially expressed KDI1 via a protein transduction domain into EGFR-expressing cells results in KDI1.EGF receptor complex formation, a slower proliferation, and reduced soft agar colony formation. Aptamer KDI1 did not summarily block the EGF receptor tyrosine kinase activity but selectively interfered with the EGF-induced phosphorylation of the tyrosine residues 845, 1068, and 1148 as well as the phosphorylation of tyrosine 317 of p46 Shc. EGF-induced phosphorylation of Stat3 at tyrosine 705 and Stat3-dependent transactivation were also impaired. Transduction of a short synthetic peptide aptamer sequence not embedded into the scaffold protein resulted in the same impairment of EGF-induced Stat3 activation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12842895     DOI: 10.1074/jbc.M301629200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

1.  Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.

Authors:  Konstantin H Dragnev; Tian Ma; Jobin Cyrus; Fabrizio Galimberti; Vincent Memoli; Alexander M Busch; Gregory J Tsongalis; Marc Seltzer; David Johnstone; Cherie P Erkmen; William Nugent; James R Rigas; Xi Liu; Sarah J Freemantle; Jonathan M Kurie; Samuel Waxman; Ethan Dmitrovsky
Journal:  Cancer Prev Res (Phila)       Date:  2011-06

2.  Oligonucleotide-directed site-specific integration of high complexity libraries into ssDNA templates.

Authors:  M B Hale; G P Nolan; R Wolkowicz
Journal:  Nucleic Acids Res       Date:  2004-01-29       Impact factor: 16.971

3.  A novel assay for the detection of anti-human platelet antigen antibodies (HPA-1a) based on peptide aptamer technology.

Authors:  Julien Thibaut; Yves Mérieux; Dominique Rigal; Germain Gillet
Journal:  Haematologica       Date:  2011-12-01       Impact factor: 9.941

Review 4.  The biological functions of the versatile transcription factors STAT3 and STAT5 and new strategies for their targeted inhibition.

Authors:  Sylvane Desrivières; Christian Kunz; Itamar Barash; Vida Vafaizadeh; Corina Borghouts; Bernd Groner
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-01       Impact factor: 2.673

Review 5.  Targeting STAT3 in cancer: how successful are we?

Authors:  Peibin Yue; James Turkson
Journal:  Expert Opin Investig Drugs       Date:  2009-01       Impact factor: 6.206

6.  Peptide-nanowire hybrid materials for selective sensing of small molecules.

Authors:  Michael C McAlpine; Heather D Agnew; Rosemary D Rohde; Mario Blanco; Habib Ahmad; Andreea D Stuparu; William A Goddard; James R Heath
Journal:  J Am Chem Soc       Date:  2008-06-25       Impact factor: 15.419

7.  Endogenous transmembrane protein UT2 inhibits pSTAT3 and suppresses hematological malignancy.

Authors:  Dongjun Lee; Ying-Hua Wang; Demetrios Kalaitzidis; Janani Ramachandran; Homare Eda; David B Sykes; Noopur Raje; David T Scadden
Journal:  J Clin Invest       Date:  2016-02-29       Impact factor: 14.808

8.  Inhibition of transforming growth factor-beta1-induced signaling and epithelial-to-mesenchymal transition by the Smad-binding peptide aptamer Trx-SARA.

Authors:  Bryan M Zhao; F Michael Hoffmann
Journal:  Mol Biol Cell       Date:  2006-06-14       Impact factor: 4.138

Review 9.  Peptide aptamers: tools to negatively or positively modulate HSPB1(27) function.

Authors:  Benjamin Gibert; Stéphanie Simon; Valeriya Dimitrova; Chantal Diaz-Latoud; André-Patrick Arrigo
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-03-25       Impact factor: 6.237

10.  Peptide aptamers as new tools to modulate clathrin-mediated internalisation--inhibition of MT1-MMP internalisation.

Authors:  Rochana D Wickramasinghe; Paul Ko Ferrigno; Christian Roghi
Journal:  BMC Cell Biol       Date:  2010-07-23       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.